Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 11/20 | 0.61 |
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25010103 | 0.97 | KDM4E (0.67) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25009345 | 0.96 | TSHR (0.70) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25010087 | 0.95 | MAPT (0.64) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25009177 | 0.94 | TSHR (0.70) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25010453 | 0.93 | KDM4E (0.71) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25010441 | 0.91 | TSHR (0.69) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25010452 | 0.89 | TSHR (0.72) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25011047 | 0.88 | KDM4E (0.74) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25009150 | 0.88 | MAPT (0.74) | KDM4ETSHRALDH1A1HTTTP53 | |
| SCHEMBL25010450 | 0.87 | TSHR (0.73) | KDM4ETSHRALDH1A1HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | KDM4E 2556/4885TSHR 4634/4885ALDH1A1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.